Related Experiment Video
Updated: Sep 24, 2025
08:58
Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression
Published on: April 18, 2025
673
Cystic fibrosis year in review 2021
1Department of Pediatrics, Children's Hospital of New Orleans, New Orleans, Louisiana, USA.
Pediatric Pulmonology
|May 2, 2022
Summary
New cystic fibrosis (CF) treatments offer hope, but not all patients qualify. Research in 2021 focused on improving modulator eligibility, early diagnosis, and managing advanced lung disease in CF patients.
Area of Science:
- Pulmonology and Genetic Medicine
- Therapeutic Modalities for Cystic Fibrosis
Background:
- Cystic Fibrosis (CF) treatment landscape has been revolutionized by highly effective modulators.
- A significant portion of CF patients remain ineligible for current modulator therapies.
- Pulmonary exacerbations and advanced lung disease persist as critical challenges for non-eligible CF individuals.
Purpose of the Study:
- To review high-impact clinical research published in 2021 concerning cystic fibrosis.
- To highlight advancements in modulator therapy eligibility and access.
- To discuss ongoing research in optimizing newborn CF diagnosis and evaluation.
Main Methods:
- Systematic review of clinical articles published in 2021.
- Focus on studies with high clinical relevance to CF patient care.
- Synthesis of research on modulator efficacy, eligibility, and challenges.
Main Results:
- Significant progress in understanding CF modulator mechanisms and expanding eligibility criteria.
- Continued research into novel diagnostic approaches for early CF detection in newborns.
- Identification of ongoing therapeutic gaps for CF patients not benefiting from current modulators.
Conclusions:
- While modulator therapies have transformed CF care, challenges remain for eligible patients.
- Optimizing newborn screening and diagnostic protocols is crucial for timely intervention.
- Further research is needed to address advanced lung disease and improve outcomes for all individuals with CF.
Keywords:
CFTR modulatorsadvanced lung diseasecystic fibrosisnewborn screeningpulmonary exacerbationsMore Related Videos
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
92
07:16Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
Published on: September 20, 2024
1.2K
Related Concept Videos
01:24Cystic Fibrosis: Management
230
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
230
01:23Cystic Fibrosis: Pathogenesis
380
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
380
01:22Chronic Obstructive Pulmonary Disease
1.5K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.5K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.0K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.0K
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.7K
01:29Chronic Pancreatitis II: Collaborative Care
133
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
133